Published on
Dec 16, 2024
Galderma adds new indication for blockbuster hope Nemluvio
Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label. Nemluvio (nemolizumab) – which was approved by the FDA in the summer for the rare skin disorder prurigo nodularis – can …
Source:
pharmaphorum
-
Neutral
